Development of therapeutics for cancer treatment

癌症治疗疗法的开发

• 批准号: 6738769
• 负责人: VIT LAUERMANN
• 金额: $ 14万
• 依托单位: RUBICON LABORATORY, INC.
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-01-26 至 2005-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6738769
• 关键词: antibody inhibitor; antibody specificity; antitumor antibody; chemical cleavage; enzyme activity; immunologic substance development /preparation; immunoregulation; monoclonal antibody; neoplasm /cancer immunotherapy; prostate neoplasms; prostate specific antigen; protein tyrosine kinase

DESCRIPTION (provided by applicant): The goal of this project is to develop novel therapy for prostate cancer. We propose to develop novel antibody-based therapeutics with high specificity for a target tumor cell. The tumor-selective antibody approach can be adapted for many antibodies and tumor types. Treatment of many solid tumors with antibodies is challenging due to difficulties with tumor-selective delivery. Proteins, to which monoclonal antibodies specifically bind, are usually over expressed on surface of cancer cells but also expressed, to some degree, on normal cells. Such expression pattern creates difficulties in the antibody delivery and decreases specificity of the therapy. The therapeutic efficacy of some antibodies is also limited due to toxicity. Higher amounts of antibodies are required to achieve the desired effects and result in increased side effects and higher cost of treatment. To improve the therapeutic efficacy, the local concentration of an antibody in a tumor site has to be increased without causing side effects. The proposed antibody-based product is activated in the tumor site and its concentration can reach levels that have desired therapeutic effects without systemic toxicity. There is urgent clinical need to enhance the efficacy of anticancer antibodies to achieve desirable cure rates for the disease. In Phase I, we will develop proposed reagents and test them invitro. In Phase II, we will test the reagents in preclinical studies evaluating treatment of tumors in animals.

描述（由申请人提供）：本项目的目标是开发前列腺癌的新疗法。我们提出开发对靶肿瘤细胞具有高特异性的新型基于抗体的治疗剂。肿瘤选择性抗体方法可适用于许多抗体和肿瘤类型。由于肿瘤选择性递送的困难，用抗体治疗许多实体瘤具有挑战性。单克隆抗体特异性结合的蛋白质通常在癌细胞表面过表达，但在一定程度上也在正常细胞上表达。这样的表达模式在抗体递送中产生困难并且降低治疗的特异性。一些抗体的治疗功效也由于毒性而受到限制。需要更高量的抗体来实现所需的效果，并导致增加的副作用和更高的治疗成本。为了提高治疗效果，必须在不引起副作用的情况下增加肿瘤部位中抗体的局部浓度。拟定的基于抗体的产品在肿瘤部位被激活，其浓度可达到具有所需治疗效果的水平，而无全身毒性。临床上迫切需要增强抗癌抗体的功效，以实现疾病的理想治愈率。在第一阶段，我们将开发拟议的试剂并进行体外测试。在第二阶段，我们将在评估动物肿瘤治疗的临床前研究中测试试剂。